- Policy
- "Korea Passing concerns…'dual pricing system' under review"
- by Lee, Jeong-Hwan Oct 17, 2025 06:10am
- Minister of Health and Welfare Jeong Eun Kyeong announced that the Ministry would strengthen administrative efforts for 'fast track National Health Insurance (NHI) listing of new drugs' and review the introduction of a 'dual pricing system' to prevent global pharmaceutical companies from "Korea Passing" of their new drugs. On October 14,
- Company
- Expanded reimb prospect for 5 indications of 'Tevimbra'
- by Eo, Yun-Ho Oct 16, 2025 06:21am
- The cancer immunotherapy 'Tevimbra' is gathering attention over whether it will receive expanded reimbursement following its previous success in the esophageal cancer indication. According to industry sources, five indications for BeOneMedicines Korea's PD-1 inhibitor immunotherapy Tevimbra (tislelizumab) are expected to be considered by
- Policy
- Bylvay granted orphan drug designation for Alagille syndrome
- by Lee, Tak-Sun Oct 16, 2025 06:21am
- From this month, Bylvay Cap (odevixibat, Ipsen Korea)&8212;which was recently listed for reimbursement as a treatment for progressive familial intrahepatic cholestasis (PFIC)&8212;has been designated as an orphan drug for treating cholestasis-associated symptoms in patients with Alagille syndrome. The orphan designation is expected to a
- Policy
- Will regulations emerge for Wegovy prescriptions?
- by Lee, Jeong-Hwan Oct 16, 2025 06:20am
- Health and Welfare Minister Eun-kyeong Jeong acknowledged the excessive prescription of the popular obesity drug Wegovy in some frontline medical institutions and pledged to devise measures to improve prescribing practices through consultation with the medical community. The minister also said that MOHW will cooperate with the Ministry of
- Policy
- MOHW Minister Jeong 'Will expedite orphan drug listings'
- by Jung, Heung-Jun Oct 16, 2025 06:20am
- The Ministry of Health and Welfare announced it will support the expedited listing of new drugs to enhance access to rare disease treatments and develop tailored measures for each rare disease. It also plans to collaborate with the Korea Disease Control and Prevention Agency to expand the legal designation of rare diseases. During the
- Policy
- "Overseas transfer of KOR genomic data by China's Novogene"
- by Lee, Jeong-Hwan Oct 16, 2025 06:20am
- Rep. Lee Ju-young of the Reform Party pointed out an issue regarding Novogene, a Chinese genomics analysis company that established a branch in Korea, that the company has no genetic analysis equipment in Korea. Rep. Lee's concern is that Novogene's holding company, BGI, was globally reported in 2021 for allegedly collecting and sharing g
- Company
- ‘Leclaza combo extends survival without chemotherapy’
- by Son, Hyung Min Oct 15, 2025 11:37am
- “The MARIPOSA study is the first clinical trial to significantly extend overall survival using two targeted therapies without chemotherapy. Discussions on EGFR-mutated lung cancer treatment will now shift to focus on overall survival.” During a recent interview with Dailypharm, Professors Byoung Chul Cho and Sun Min Lim of Yonsei Cancer
- Company
- Will the MM drug Elrexfio be reimbursed this time?
- by Eo, Yun-Ho Oct 15, 2025 06:12am
- Whether progress will be made for the new multiple myeloma drug Elrexfio (elranatamab) in its second attempt to secure reimbursement in Korea is gathering attention. According to industry sources, Pfizer Korea's bispecific antibody therapy Elrexfio (elranatamab) is expected to be submitted for reimbursement review to the Health Insurance
- Opinion
- [Op-Ed] Patients, no time left for 'new drug comb therapies'
- by Eo, Yun-Ho Oct 15, 2025 06:11am
- "My father (in his 60s), who has been diagnosed with urothelial carcinoma, is paying 10 million won every three weeks for combination cancer therapy that is non-reimbursed. The disaster medical expense program provided the cost. However, we feel helpless upon the news that the fund is being delayed." This is part of a public complaint file
- Policy
- New Divisions for Essential & Public Healthcare proposed
- by Lee, Jeong-Hwan Oct 15, 2025 06:11am
- The Ministry of Health and Welfare has decided to establish a new director-level organization, the ‘Regional, Essential, and Public Healthcare Policy Office,’ to ensure the success of the Lee Jae-myung administration's national policy task of people-focused healthcare reform. It has been confirmed that this request has been submitted to th
